Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 6/20 | 0.45 |
| ▸ | NOS3 | P29474 | 5/20 | 0.45 |
| ▸ | NOS1 | P29475 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2623102 | 0.84 | NOS2 (0.54) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL21672278 | 0.76 | NOS2 (0.54) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL2623106 | 0.76 | NOS2 (0.63) | NOS2NOS3NOS1 | |
| SCHEMBL18068188 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL22029272 | 0.74 | NOS2 (0.45) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL239913 | 0.74 | NOS2 (0.45) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL14072803 | 0.71 | NOS3 (0.42) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL9521798 | 0.65 | NOS2 (0.52) | NOS2NOS3NOS1RAB9ANPC1 | |
| SCHEMBL2528347 | 0.65 | — | — | |
| SCHEMBL25086836 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542552-B1 | SUBSTITUTED AZA-BICYCLIC IMIDAZOLE DERIVATIVES USEFUL AS TRPM8 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-15 | — | — | EP | disclosed |
| WO-2011041512-A2 | COMPOSITIONS AND METHODS FOR TREATING MLV-INFECTION, AND PREVENTING AND TREATING MLV-INITIATED DISEASES | EMORY UNIVERSITY (US) | 2011-04-07 | — | — | WO | disclosed |